Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Br J Pharmacol ; 180(14): 1819-1831, 2023 07.
Article in English | MEDLINE | ID: mdl-36645812

ABSTRACT

BACKGROUND AND PURPOSE: Incubation of craving, the progressive increase in drug seeking over the first weeks of abstinence, is associated with temporal changes during abstinence in the activity of several structures involved in drug-seeking behaviour. Decreases of dopamine (DA) release and DA neuronal activity (hypodopaminergic state) have been reported in the ventral tegmental area (VTA) during cocaine abstinence, but the mechanisms underlying these neuroadaptations are not well understood. We investigated the potential involvement of a VTA inhibiting circuit (basolateral amygdala [BLA]-ventral pallidum [VP] pathway) in the hypodopaminergic state associated with abstinence from chronic cocaine. EXPERIMENTAL APPROACH: In a model of cocaine self-administration, we performed in vivo electrophysiological recordings of DA VTA neurons and BLA neurons from anaesthetised rats during early and protracted abstinence and evaluated the involvement of the BLA-VP pathway using a pharmacological approach. KEY RESULTS: We found significant decreases in VTA DA population activity and significant increases in BLA activity after protracted but not after short-term abstinence from chronic cocaine. The decrease in VTA DA activity was restored by pharmacological inhibition of the activity of either the BLA or the VP, suggesting that these regions exert a negative influence on DA activity. CONCLUSION AND IMPLICATIONS: Our study sheds new lights on neuroadaptations occurring during incubation of craving leading to relapse. In particular, we describe the involvement of the BLA-VP pathway in cocaine-induced decreases of DA activity in the VTA. This study adds important information about the specific brain network dysfunctions underlying hypodopaminergic activity during abstinence.


Subject(s)
Basal Forebrain , Cocaine , Rats , Animals , Cocaine/pharmacology , Ventral Tegmental Area/metabolism , Rats, Sprague-Dawley , Basal Forebrain/metabolism , Dopamine/metabolism , Dopaminergic Neurons/metabolism , Amygdala/metabolism
2.
Psychopharmacology (Berl) ; 239(4): 1009-1018, 2022 Apr.
Article in English | MEDLINE | ID: mdl-33768375

ABSTRACT

RATIONALE: In rodents, environmental enrichment (EE) produces both preventive and curative effects on drug addiction, and this effect is believed to depend at least in part on EE's actions on the stress system. OBJECTIVES: This study investigated whether exposure to EE during abstinence reduces methamphetamine seeking after extended self-administration. In addition, we investigated whether these effects are associated with alterations in the levels of glucocorticoid receptors (GR) in the brain and whether administration of GR antagonists blocks methamphetamine relapse. METHODS: We allowed rats to self-administer methamphetamine for twenty 14-h sessions. After 3 weeks of abstinence either in standard (SE) or EE conditions, we measured methamphetamine seeking in a single 3-h session. Then, we used western blot techniques to measure GR levels in several brain areas. Finally, in an independent group of rats, after methamphetamine self-administration and abstinence in SE, we administered the GR antagonist mifepristone, and we investigated methamphetamine seeking. RESULTS: Exposure to EE reduced methamphetamine seeking and reversed methamphetamine-induced increases in GR levels in the ventral and dorsal hippocampus. In addition, EE decreased GR levels in the amygdala in drug-naive animals, but this effect was prevented by previous exposure to methamphetamine. Administration of mifepristone significantly decreased methamphetamine seeking. CONCLUSIONS: The anti-craving effects of EE are paralleled by restoration of methamphetamine-induced dysregulation of GR in the hippocampus. These results provide support for the hypothesis that the effect of EE on methamphetamine relapse is at least in part mediated by EE's action on the brain stress system.


Subject(s)
Methamphetamine , Animals , Drug-Seeking Behavior , Methamphetamine/pharmacology , Mifepristone/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Glucocorticoid , Recurrence , Self Administration
3.
Int J Neuropsychopharmacol ; 24(6): 499-504, 2021 07 14.
Article in English | MEDLINE | ID: mdl-33305794

ABSTRACT

The chronic relapsing nature of cocaine addiction suggests that chronic cocaine exposure produces persistent neuroadaptations that may be temporally and regionally dynamic in brain areas such as the dopaminergic (DA) system. We have previously shown altered metabolism of DA-target structures, the ventral and dorsal striatum, between early and late abstinence. However, specific changes within the midbrain DA system were not investigated. Here, we investigated potential time- and region-specific changes of activity in the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc) in rats that had extended or limited access to cocaine and later underwent a period of abstinence. We found that DA activity is decreased only in the VTA in rats with extended access to cocaine, with no changes in SNc DA activity. These changes in VTA DA activity may participate in the negative emotional state and the incubation of drug seeking that occur during abstinence from cocaine.


Subject(s)
Cocaine-Related Disorders/metabolism , Cocaine/administration & dosage , Dopamine Uptake Inhibitors/administration & dosage , Dopamine/metabolism , Pars Compacta/metabolism , Ventral Tegmental Area/metabolism , Animals , Behavior, Animal/physiology , Male , Rats , Rats, Sprague-Dawley , Self Administration
4.
J Neural Transm (Vienna) ; 126(4): 481-516, 2019 04.
Article in English | MEDLINE | ID: mdl-30569209

ABSTRACT

Among the neurotransmitters involved in addiction, dopamine (DA) is clearly the best known. The critical role of DA in addiction is supported by converging evidence that has been accumulated in the last 40 years. In the present review, first we describe the dopaminergic system in terms of connectivity, functioning and involvement in reward processes. Second, we describe the functional, structural, and molecular changes induced by drugs within the DA system in terms of neuronal activity, synaptic plasticity and transcriptional and molecular adaptations. Third, we describe how genetic mouse models have helped characterizing the role of DA in addiction. Fourth, we describe the involvement of the DA system in the vulnerability to addiction and the interesting case of addiction DA replacement therapy in Parkinson's disease. Finally, we describe how the DA system has been targeted to treat patients suffering from addiction and the result obtained in clinical settings and we discuss how these different lines of evidence have been instrumental in shaping our understanding of the physiopathology of drug addiction.


Subject(s)
Dopamine/metabolism , Substance-Related Disorders/metabolism , Substance-Related Disorders/physiopathology , Animals , Behavior, Addictive/metabolism , Behavior, Addictive/physiopathology , Humans
5.
Int J Neuropsychopharmacol ; 20(12): 1036-1046, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29106542

ABSTRACT

Anhedonia is considered a core feature of major depressive disorder, and the dopamine system plays a pivotal role in the hedonic deficits described in this disorder. Dopaminergic activity is complex and under the regulation of multiple brain structures, including the ventral subiculum of the hippocampus and the basolateral amygdala. Whereas basic and clinical studies demonstrate deficits of the dopaminergic system in depression, the origin of these deficits likely lies in dysregulation of its regulatory afferent circuits. This review explores the current information regarding the afferent modulation of the dopaminergic system and its relevance to major depressive disorder, as well as some of the system-level effects of novel antidepressants such as agomelatine and ketamine.


Subject(s)
Brain/metabolism , Depressive Disorder, Major/metabolism , Depressive Disorder, Major/pathology , Dopamine/metabolism , Animals , Humans
6.
Neuropsychopharmacology ; 42(10): 1981-1990, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28553833

ABSTRACT

The chronic and relapsing nature of addiction suggests that drugs produce persistent adaptations in the brain that make individuals with drug addiction particularly sensitive to drug-related cues and stress and incapable of controlling drug-seeking and drug-taking behavior. In animal models, several long-lasting neuroadaptations have been described. However, few studies have used brain-imaging techniques to provide a complete picture of brain functioning in the course of withdrawal from cocaine. In this study, we allowed rats to self-administer cocaine under short-access (1-h/day) or long-access (6-h/day) conditions and used 2-deoxy-2-(18F)fluoro-d-glucose (18FDG) positron emission tomography scanning to investigate the longitudinal changes in metabolic activity 1 and 4 weeks after discontinuation of cocaine self-administration. We found that compared to naive rats, both long-access and short-access rats showed significant disruptions in basal brain metabolic activity. However, compared to short-access, long-access rats showed more intense, and long-lasting neuroadaptations in a network of brain areas. In particular, abstinence from extended access to cocaine was associated with decreased metabolic activity in the anterior cingulate cortex, the insular cortex, and the dorsolateral striatum, and increased metabolic activity in the mesencephalon, amygdala, and hippocampus. This pattern is strikingly similar to that described in humans that has led to the proposal of the Impaired Response Inhibition and Salience Attribution model of addiction. These results demonstrate that extended access to cocaine leads to persistent neuroadaptations in brain regions involved in motivation, salience attribution, memory, stress, and inhibitory control that may underlie increased risks of relapse.


Subject(s)
Brain/metabolism , Cocaine-Related Disorders/metabolism , Animals , Brain/diagnostic imaging , Brain/drug effects , Brain Mapping , Cocaine/administration & dosage , Cocaine-Related Disorders/diagnostic imaging , Disease Models, Animal , Dopamine Uptake Inhibitors/administration & dosage , Fluorodeoxyglucose F18 , Longitudinal Studies , Male , Positron-Emission Tomography , Radiopharmaceuticals , Rats, Sprague-Dawley , Self Administration
8.
Neuropsychopharmacology ; 41(2): 619-27, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26129677

ABSTRACT

Drug addiction is a chronic disorder characterized by a cycle composed of drug seeking, intoxication with drug taking and withdrawal associated with negative affect. Numerous studies have examined withdrawal/negative affect after chronic use; however, very few have examined the effect of acute administration on the negative affective state after acute drug withdrawal. One dose of amphetamine was injected into Sprague-Dawley rats. Despair behavior using the modified forced swim test (FST) and dopamine (DA) activity in the ventral tegmental area using in vivo electrophysiological recordings were studied 18, 48 and 72 h after injection of amphetamine. The effects of inactivation of the basolateral amygdala (BLA) and ketamine administration on VTA DA neuron activity and passivity in the modified FST were examined. Eighteen hours following amphetamine withdrawal, there was a substantial decrease in the number of active DA neurons, as well as an increase in time spent immobile in the modified FST, which returned to baseline after 72 h. Inactivation of the BLA after acute amphetamine prevented the decrease in DA neuron tonic activity. Injection of ketamine also prevented the decrease in DA population activity but had no effect on immobility measured in the modified FST. The data support a model in which the negative affective state following acute amphetamine withdrawal is associated with a decrease in DA neuron population activity, driven by hyperactivity of the BLA. Although ketamine reversed the hypodopaminergic state following withdrawal, the failure to reduce immobility in the modified FST indicates that different processes underlying negative emotional state may exist between depression and drug withdrawal.


Subject(s)
Amphetamine-Related Disorders/drug therapy , Amphetamine/toxicity , Central Nervous System Stimulants/toxicity , Excitatory Amino Acid Antagonists/pharmacology , Ketamine/pharmacology , Substance Withdrawal Syndrome/drug therapy , Action Potentials/drug effects , Action Potentials/physiology , Amphetamine-Related Disorders/physiopathology , Animals , Basolateral Nuclear Complex/drug effects , Basolateral Nuclear Complex/physiopathology , Disease Models, Animal , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/physiology , Male , Motor Activity/drug effects , Motor Activity/physiology , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Substance Withdrawal Syndrome/physiopathology , Time Factors , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/physiopathology
9.
Proc Biol Sci ; 282(1805)2015 Apr 22.
Article in English | MEDLINE | ID: mdl-25788601

ABSTRACT

Although, historically, the norepinephrine system has attracted the majority of attention in the study of the stress response, the dopamine system has also been consistently implicated. It has long been established that stress plays a crucial role in the pathogenesis of psychiatric disorders. However, the neurobiological mechanisms that mediate the stress response and its effect in psychiatric diseases are not well understood. The dopamine system can play distinct roles in stress and psychiatric disorders. It is hypothesized that, even though the dopamine (DA) system forms the basis for a number of psychiatric disorders, the pathology is likely to originate in the afferent structures that are inducing dysregulation of the DA system. This review explores the current knowledge of afferent modulation of the stress/DA circuitry, and presents recent data focusing on the effect of stress on the DA system and its relevance to psychiatric disorders.


Subject(s)
Afferent Pathways/physiology , Dopamine/metabolism , Hypothalamo-Hypophyseal System/physiology , Humans , Stress, Psychological
10.
Biol Psychiatry ; 76(12): 927-36, 2014 Dec 15.
Article in English | MEDLINE | ID: mdl-24931705

ABSTRACT

BACKGROUND: One of the most novel and exciting findings in major depressive disorder research over the last decade is the discovery of the fast-acting and long-lasting antidepressant effects of ketamine. Indeed, the therapeutic effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer to be expressed, with about a third of major depressive disorder patients resistant to treatment. Clinical studies have shown that a low dose of ketamine exhibits fast-acting relatively sustained antidepressant action, even in treatment-resistant patients. However, the mechanisms of ketamine action at a systems level remain unclear. METHODS: Wistar-Kyoto rats were exposed to inescapable, uncontrollable footshocks. To evaluate learned helplessness behavior, we used an active avoidance task in a shuttle box equipped with an electrical grid floor. After helplessness assessment, we performed in vivo electrophysiological recordings first from ventral tegmental area dopaminergic (DA) neurons and second from accumbens neurons responsive to fimbria stimulation. Ketamine was injected and tested on helpless behavior and electrophysiological recordings. RESULTS: We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression. We show that part of the antidepressant effect of ketamine is via the DA system. Indeed, injection of ketamine restores a decreased dopamine neuron population activity, as well as synaptic plasticity (long-term potentiation) in the hippocampus-accumbens pathway, via, in part, activation of D1 receptors. CONCLUSIONS: This work provides a unique systems perspective on the mechanisms of ketamine on a disrupted limbic system.


Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Dopaminergic Neurons/drug effects , Ketamine/therapeutic use , Long-Term Potentiation/drug effects , Action Potentials/drug effects , Animals , Antidepressive Agents/pharmacology , Benzazepines/pharmacology , Brain/pathology , Depression/etiology , Depression/pathology , Disease Models, Animal , Dopamine Agonists/pharmacology , Dopaminergic Neurons/physiology , Electroshock/adverse effects , Helplessness, Learned , Ketamine/pharmacology , Long-Term Potentiation/physiology , Male , Neural Pathways/drug effects , Rats , Rats, Inbred WKY , Reaction Time/drug effects , Time Factors
11.
Cereb Cortex ; 24(4): 968-77, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23236209

ABSTRACT

Schizophrenia is characterized by alterations in cortico-limbic processes believed to involve modifications in activity within the prefrontal cortex (PFC) and the hippocampus. The nucleus accumbens (NAc) integrates information from these 2 brain regions and is involved in cognitive and psychomotor functions that are disrupted in schizophrenia, indicating an important role for this structure in the pathophysiology of this disorder. In this study, we used in vivo electrophysiological recordings from the NAc and the PFC of adult rats and the MAM developmental disruption rodent model of schizophrenia to explore the influence of the medial PFC on the hippocampal-accumbens pathway. We found that, in MAM-treated rats, tetanization of hippocampal inputs to the NAc produce opposite synaptic plasticity compared with controls, which is a consequence of alterations in the hippocampal-mPFC pathway. Moreover, we show that administration of the D2-receptor-blocking antipsychotic drug sulpiride either systemically or directly into the mPFC reverses the alterations in the MAM rat. Therefore, specific disruptions in cortical and hippocampal inputs in the MAM-treated rat abnormally alter plasticity in subcortical structures. Moreover, our results suggest that, in the presence of antipsychotic drugs, the disrupted plasticities are normalized, supporting a role for this mechanism in antipsychotic drug action in schizophrenia.


Subject(s)
Hippocampus/pathology , Neuronal Plasticity/physiology , Nucleus Accumbens/pathology , Prefrontal Cortex/pathology , Schizophrenia/pathology , Synapses/pathology , Analysis of Variance , Animals , Disease Models, Animal , Female , Male , Methylazoxymethanol Acetate/toxicity , Neural Pathways/pathology , Neurons/physiology , Neurotoxins/toxicity , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Prenatal Exposure Delayed Effects/physiopathology , Rats , Rats, Sprague-Dawley , Schizophrenia/etiology
13.
Int J Neuropsychopharmacol ; 16(3): 507-12, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23067577

ABSTRACT

The nucleus accumbens (NAc) receives converging inputs from the medial prefrontal cortex (mPFC) and the hippocampus which have competitive interactions in the NAc to influence motivational drive. We have previously shown altered synaptic plasticity in the hippocampal-NAc pathway in the methylazoxymethanol acetate (MAM) developmental model of schizophrenia in rodents that is dependent on cortical inputs. Thus, because mPFC-hippocampal balance is known to be partially altered in this model, we investigated potential pathological changes in the hippocampal influence over cortex-driven NAc spike activity. Here we show that the reciprocal interaction between the hippocampus and mPFC is absent in MAM animals but is able to be reinstated with administration of the antipsychotic drug, sulpiride. The lack of interaction between these structures in this model could explain the attentional deficits in schizophrenia patients and shed light onto their inability to focus on a single task.


Subject(s)
Antipsychotic Agents/therapeutic use , Disease Models, Animal , Hippocampus/physiology , Prefrontal Cortex/physiology , Schizophrenia/drug therapy , Sulpiride/therapeutic use , Animals , Antipsychotic Agents/pharmacology , Female , Hippocampus/drug effects , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Male , Methylazoxymethanol Acetate/toxicity , Prefrontal Cortex/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Schizophrenia/chemically induced , Schizophrenia/physiopathology , Sulpiride/pharmacology
14.
Neuron ; 71(5): 766-8, 2011 Sep 08.
Article in English | MEDLINE | ID: mdl-21903070

ABSTRACT

Neural synchronization plays an important role in information flow in the nervous system under healthy and pathological conditions. In this issue of Neuron, Gittis et al. show that reorganization of striatal microcircuits promotes synchronous activity and may underlie the pathological network oscillations at the root of motor symptoms described in Parkinson's disease.

15.
Ann N Y Acad Sci ; 1216: 114-21, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21272015

ABSTRACT

Stress is one of the major factors in drug abuse, particularly in relapse and drug-seeking behavior. However, the mechanisms underlying the interactions between stress and drug abuse are unclear. For many years, studies have focused on the role of the dopaminergic reward system in drug abuse. Our results, for example, show that increased dopaminergic activity is induced by drug sensitization and different stressors via potentiation of the ventral subiculum-nucleus accumbens (NAc) pathway. Although the role of the norepinephrine (NE) system in stress is well known, its involvement in drug abuse has received less attention. This review explores the different mechanisms by which stressors can modulate the ventral subiculum-accumbens pathway, and how these modulations can induce alterations in the behavioral response to drug administration. In particular, we will focus on two main afferents to the NAc, the basolateral amygdala and the ventral subiculum of the hippocampus, and their interactions with the locus coeruleus-norepinephrine system.


Subject(s)
Amygdala/metabolism , Behavior, Addictive/etiology , Hippocampus/metabolism , Stress, Psychological/complications , Behavior, Addictive/metabolism , Disease Susceptibility/metabolism , Dopamine/metabolism , Drug-Seeking Behavior , Humans , Norepinephrine/metabolism , Nucleus Accumbens/metabolism , Reward , Stress, Psychological/metabolism , Substance-Related Disorders/metabolism
16.
Mov Disord ; 25(11): 1568-76, 2010 Aug 15.
Article in English | MEDLINE | ID: mdl-20623773

ABSTRACT

Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic L-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic L-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to L-dopa therapy.


Subject(s)
Antiparkinson Agents/adverse effects , Corpus Striatum/physiopathology , Dyskinesia, Drug-Induced/pathology , Dyskinesia, Drug-Induced/physiopathology , Levodopa/adverse effects , Neuronal Plasticity/drug effects , Action Potentials/drug effects , Action Potentials/physiology , Animals , Behavior, Animal/drug effects , Cholera Toxin/metabolism , Corpus Striatum/cytology , Corpus Striatum/drug effects , Disease Models, Animal , Dyskinesia, Drug-Induced/etiology , Fluorescent Dyes/metabolism , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Neuronal Plasticity/physiology , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Neurons/physiology , Oxidopamine/toxicity , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Rats , Substantia Nigra/drug effects , Substantia Nigra/physiopathology , Tyrosine 3-Monooxygenase/metabolism
17.
PLoS One ; 4(7): e6208, 2009 Jul 09.
Article in English | MEDLINE | ID: mdl-19587792

ABSTRACT

BACKGROUND: Clinical treatments with typical antipsychotic drugs (APDs) are accompanied by extrapyramidal motor side-effects (EPS) such as hypokinesia and catalepsy. As little is known about electrophysiological substrates of such motor disturbances, we investigated the effects of a typical APD, alpha-flupentixol, on the motor behavior and the neuronal activity of the whole basal ganglia nuclei in the rat. METHODS AND FINDINGS: The motor behavior was examined by the open field actimeter and the neuronal activity of basal ganglia nuclei was investigated using extracellular single unit recordings on urethane anesthetized rats. We show that alpha-flupentixol induced EPS paralleled by a decrease in the firing rate and a disorganization of the firing pattern in both substantia nigra pars reticulata (SNr) and subthalamic nucleus (STN). Furthermore, alpha-flupentixol induced an increase in the firing rate of globus pallidus (GP) neurons. In the striatum, we recorded two populations of medium spiny neurons (MSNs) after their antidromic identification. At basal level, both striato-pallidal and striato-nigral MSNs were found to be unaffected by alpha-flupentixol. However, during electrical cortico-striatal activation only striato-pallidal, but not striato-nigral, MSNs were found to be inhibited by alpha-flupentixol. Together, our results suggest that the changes in STN and SNr neuronal activity are a consequence of increased neuronal activity of globus pallidus (GP). Indeed, after selective GP lesion, alpha-flupentixol failed to induce EPS and to alter STN neuronal activity. CONCLUSION: Our study reports strong evidence to show that hypokinesia and catalepsy induced by alpha-flupentixol are triggered by dramatic changes occurring in basal ganglia network. We provide new insight into the key role of GP in the pathophysiology of APD-induced EPS suggesting that the GP can be considered as a potential target for the treatment of EPS.


Subject(s)
Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/physiopathology , Basal Ganglia/physiopathology , Flupenthixol/adverse effects , Animals , Basal Ganglia Diseases/chemically induced , Corpus Striatum/drug effects , Male , Rats , Rats, Wistar
18.
J Neurosci ; 28(39): 9797-805, 2008 Sep 24.
Article in English | MEDLINE | ID: mdl-18815264

ABSTRACT

The nucleus accumbens (NAc) is an integral part of limbic circuits proposed to play a central role in the pathophysiology of schizophrenia, and is positioned to integrate information from limbic and cortical regions, including the medial prefrontal cortex (mPFC) and the hippocampus. The ventral subiculum (vSub) of the hippocampus, in particular, is proposed to gate information flow within the NAc, a factor that is disrupted in models of schizophrenia. Using in vivo extracellular recordings in anesthetized rats, we examined the response of NAc neurons to vSub stimulation and how this is modulated by the mPFC. We found that inactivation of mPFC by tetrodotoxin attenuates the ability of the vSub to drive spike firing in the NAc. Thus, a contribution of the mPFC is required for the activation of NAc by the vSub. However, when long-term potentiation is induced in the vSub-NAc pathway, the vSub is now capable of driving the NAc without the participation of the mPFC. Moreover, this interaction is dependent on activation of dopaminergic D(2) receptors in the NAc. This work demonstrates the critical role of the mPFC in the ability of vSub to drive NAc neurons in normal anesthetized animals. One model of schizophrenia posits that vSub hyperactivity may underlie both the hyperdopaminergic state and disruption of information flow in this circuit in schizophrenia. Therefore, inactivation of the mPFC, as would occur with mPFC leukotomy in schizophrenia, may prevent the abnormal vSub drive of the NAc.


Subject(s)
Hippocampus/physiology , Neural Pathways/physiology , Nucleus Accumbens/physiology , Prefrontal Cortex/physiology , Action Potentials/drug effects , Analysis of Variance , Anesthetics, Local/pharmacology , Animals , Dopamine Antagonists , Dose-Response Relationship, Radiation , Electric Stimulation/methods , Long-Term Potentiation/drug effects , Long-Term Potentiation/radiation effects , Male , Neural Pathways/drug effects , Neurons/drug effects , Neurons/physiology , Nucleus Accumbens/cytology , Prefrontal Cortex/drug effects , Rats , Rats, Sprague-Dawley , Sulpiride/pharmacology , Tetrodotoxin/pharmacology
19.
Schizophr Res ; 105(1-3): 289-383, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18819775

ABSTRACT

The Schizophrenia International Research Society held its first scientific conference in Venice, Italy, June 21 to 25th, 2008. A wide range of controversial topics were presented in overlapping and plenary oral sessions. These included new genetic studies, controversies about early detection of schizophrenia and the prodrome, treatment issues, clinical characteristics, cognition, neuropathology and neurophysiology, other etiological considerations, substance abuse co-morbidity, and animal models for investigating disease etiology and for use as targets in drug studies. Young investigators in the field were awarded travel grants to participate in the congress and one of their roles was to summarize the oral sessions and subsequent discussions. The reports that follow are the culmination of this work produced by 30 young investigators who attended the congress. It is hoped that these summaries will be useful synopses of what actually occurred at the congress for those who did not attend each session or were unable to be present. The abstracts of all presentations, as submitted by the authors a few months prior, were previously published as supplement 2 to volume 102/1-3, June 2008.


Subject(s)
Congresses as Topic , Schizophrenia , Humans , Italy , Societies, Medical
20.
J Neurosci ; 27(36): 9595-606, 2007 Sep 05.
Article in English | MEDLINE | ID: mdl-17804620

ABSTRACT

The subthalamic nucleus (STN) plays a key role in the pathophysiology of Parkinson's disease. The modulation of the STN by norepinephrine, however, is unknown. The present study aims at characterizing the effects of systemic administration of noradrenergic agents on locomotor activity and on in vivo extracellularly recorded STN neuronal activity in intact and 6-hydroxydopamine (6-OHDA)-lesioned rats. Using selective agonists and antagonists of alpha1 and alpha2 adrenergic receptors (ARs), we show that STN neurons have functional alpha1- and alpha2-AR controlling STN firing with an impact on locomotor activity. We further demonstrate that those systemic effects are supported, at least in part, by a direct modulation of STN neuronal activity, using patch-clamp recordings of STN neurons in brain slices. These findings support the premise that hypokinesia is associated with an increased STN neuronal activity, and that improvements of parkinsonian motor abnormalities are associated with a decrease in STN activity. Our data challenge assumptions about the role of alpha1-AR and alpha2-AR in the regulation of STN neurons in both intact and 6-OHDA-lesioned rats and further ground the rationale for using alpha2-AR noradrenergic antagonists in Parkinson's disease, albeit via an unexpected mechanism.


Subject(s)
Behavior, Animal/drug effects , Norepinephrine/metabolism , Oxidopamine , Parkinsonian Disorders/physiopathology , Subthalamic Nucleus/metabolism , Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Animals , Electrophysiology , Hypokinesia/chemically induced , Hypokinesia/physiopathology , Immunohistochemistry , Male , Medial Forebrain Bundle/drug effects , Motor Activity/drug effects , Neurons/drug effects , Neurons/metabolism , Organ Culture Techniques , Parkinsonian Disorders/chemically induced , Patch-Clamp Techniques , Rats , Rats, Wistar , Receptors, Adrenergic, alpha-1/drug effects , Receptors, Adrenergic, alpha-1/metabolism , Receptors, Adrenergic, alpha-2/drug effects , Receptors, Adrenergic, alpha-2/metabolism , Subthalamic Nucleus/drug effects , Synaptic Transmission/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL